GARFIELD-AF registry

GARFIELD-AF was the largest prospective registry of patients with newly diagnosed atrial fibrillation

Back to GARFIELD-AF

Keep Up to Date Login

Search for:

Home
- - The TRI team continues to publish papers based on data accrued during the study (#50 was published in April 2021). Click on a branch of the tree to access the papers associated with that area.
    Burden of Disease
    Risk Stratification
    Treatment Practices
    Therapy Persistence
    Clinical Outcomes
    Geographic Differences
    Health Economics
About
Risk Calculator
Publications & Presentations
Newsletters
Media
Community Page

Comparing Rivaroxaban and Apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria | ← ESC Congress Presentations

SDamineni@tri-london.ac.uk | 16 Sep 21

ESC-2021_Trial-Criteria-2-Selection-criteria-ARISTOTLE-ROCKET_v1.3.2_TRI_AuthorComs.pdf

Global status

Total patients 57,262

Recruitment Recruitment closed

Follow-up
Study end: 2018

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

info@tri-london.ac.uk Contact Us

Keep up to date

Keep Up to Date

Funding

The GARFIELD-AF registry was funded by an unrestricted research grant from Bayer AG, and the ongoing work is supported by the Thrombosis Research Institute.

About TRI
Cookie Notice
Privacy Policy
Terms of Use

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup

Please see our Privacy Policy and Cookie Policy

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

E: garfield@tri-london.ac.uk
T: 0203 198 9947

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.